Mesenchymal Stem Cell Secretome In Severe Cases of COVID-19

• Status: Completed
• Trial end date: 2021-11-14
• Target enrollment: 0
• Participant gender: All

Summary

This study is a multi-centre randomized controlled trial involving severe covid-19 patients. The intervention group will receive mesenchymal stem cell secretomes and standard covid-19 therapy, while the control group receive placebo and standard covid-19 therapy. Clinical presentation, inflamatory marker, laboratory and radiological parameters, RT-PCR conversion, safety profile, and mortality rate will be monitored for a maximum of 14 days after intervention.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Indonesia University

Criteria

Inclusion Criteria:

1. All individuals aged 18 to 65 years

2. It has been confirmed positive for COVID-19 by throat swab / sputum / brochoalveolar lavage (BAL) with real-time reverse transcription polymerase chain reaction (RT-PCR)

3. Categorized as a severe case of COVID-19 patient

4. Agree to participate and sign the informed consent

Exclusion Criteria:

1. History of allergy to penicillin, streptomycin, and amphotericin-B

2. Have any cancer conditions

3. Active in other intervention studies

4. Have had other intervention studies in the last 3 months